Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare, serious condition that can lead to excessive bleeding in fetuses and newborns. It is caused by a mismatch between an expectant mother and her fetus in a specific human platelet antigen, most commonly HPA-1. There is currently no approved therapy for the prevention or treatment of patients with FNAIT.
The stock we are bringing to your attention today is that of Rallybio Corp. (RLYB), a clinical-stage biotechnology company developing therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia.
For comments and feedback contact: editorial@rttnews.com
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.